Sandoz Reviews Insulin Access, Cost, and Biosimilar Potential

December 07, 2021

In a review, Sandoz researchers discuss lingering barriers that prevent insulin prices from falling to more affordable levels.

China Regulators Approve Henlius Bevacizumab Biosimilar Hanbeitai
Dr Steven Yates on the 340B Drug Pricing Program
The Top 5 Biosimilar Articles for the Week of November 29
Study: Medicare Consolidated Biosimilar Payment Codes Would Save Money